China Pharma Holdings, Inc. Reports Third Quarter 2019 Financial Results

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

China Pharma Holdings, Inc. Reports Third Quarter 2019 Financial Results

PR Newswire

HAIKOU CITY, China, Nov. 15, 2019 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended September 30, 2019.

Third Quarter Highlights

  • Revenue increased by 3.4% to $2.4 million in the third quarter 2019 from $2.3 million in the same period of 2018;
  • Gross margin was 15.7% in the third quarter 2019, compared to 22.3% in the same period of 2018;
  • Loss from operations was $0.6 million in the third quarter 2019 compared to $1.9 million in the same period of 2018, an improvement of $1.3 million;
  • Net loss was $0.7 million in the third quarter 2019 compared to $1.9 million in the same period of 2018. Loss per common share was $0.02 per basic and diluted share in the third quarter 2019, compared to $0.04 per basic and diluted share in the same period of 2018.

Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "We experienced negative effects on our sales from the strict implementation of the government policy of controlling the proportion of the spending on drugs to the patients' total expenditures in hospitals in recent quarters. Management endeavors to vigorously promote sales through active participation in recent provincial market openings to solicit new drug tender offers and allow China Pharma to expand its presence in these markets." Ms. Li continued, "In addition, we are experiencing sustained pressure from the more stringent requirements of drug registration standards, consistency evaluations, which has created a challenging environment in our industry during this period. We will continue actively adapting to the state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market, in order to optimize our development strategy. We will simultaneously actively implement the launch of our nutrition product."

Third Quarter Results

Revenue increased by 3.4% to $2.4 million for the three months ended September 30, 2019, as compared to $2.3 million for the three months ended September 30, 2018.

Gross profit for the three months ended September 30, 2019 was $0.4 million, as compared to $0.5 million during the same period in 2018. Our gross profit margin in the three months ended September 30, 2019 was 15.7% as compared to 22.3% during the same period in 2018. The decrease in our gross profit margin was mainly due to the increased ratio of fixed cost to revenue.

Our selling expenses for the three months ended September 30, 2019 and 2018 were $0.6 million and $0.9 million, respectively. Selling expenses accounted for 25.8% of the total revenue in the three months ended September 30, 2019, as compared to 40.3% during the same period in 2018.

Our general and administrative expenses were $0.3 million for each of the three months ended September 30, 2019 and 2018. General and administrative expenses accounted for 14.0% and 14.2% of our total revenues in the three months ended September 30, 2019 and 2018, respectively.

Our research and development expenses for the three months ended September 30, 2019 were $0.04 million, as compared to $0.06 million in the same period in 2018. Research and development expenses accounted for 1.7% and 2.7% of our total revenues in the three months ended September 30, 2019 and 2018, respectively. The consistency evaluations discussed under the "Business Overview & Recent Developments" section hereof is expected to have a significant impact on all generic products not only in our pipeline products, but also throughout the existing Chinese market for similar generic products. Because of the continuous introduction of detailed implementation rules under this policy, our pipeline products did not experience any further development in the third quarter of 2019.

Our bad debt expenses for the three months ended September 30, 2019 was $0.03 million, as compared to $1.13 million for the same period in 2018. The decrease of bad debt expenses in this period was mainly due to the decrease in the amount of accounts receivable that is turning to over 2 years old in this period. Our bad debt allowance estimate requires 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts receivable that are greater than 720 days old.

Net loss for the three months ended September 30, 2019 was $0.7 million, or $0.02 per basic and diluted common share, as compared to a net loss of $1.9 million, or $0.04 per basic and diluted common share, for the same period a year ago. The decrease in net loss was mainly the result of controls on expenditures outweighed the impact of decrease in gross profit margin.

Nine Months Results

For the nine months ended September 30, 2019, our sales revenue was $7.9 million, which represented a decrease of $1.2 million, or 13.3%, from the $9.1 million in the corresponding period of 2018.

Gross profit for the nine months ended September 30, 2019 was $1.2 million, compared to $2.1 million in the same period of 2018. Gross profit margins for the nine months ended September 30, 2019 and 2018 were 15% and 24%, respectively.

Our net losses for the nine months ended September 30, 2019 and 2018 were $2.0 million and $3.2 million, respectively, which represented an improvement of $1.2 million for the period in 2019. This improvement was mainly due to the decrease of bad debt expenses in this period.

Financial Condition

As of September 30, 2019, the Company had cash and cash equivalents of $0.8 million compared to $1.2 million as of December 31, 2018.

As of September 30, 2019, our net accounts receivable was $0.7 million, compared to $0.9 million as of December 31, 2018.

For the nine months ended September 30, 2019, cash flow from operating activities was $1.4 million, as compared to $1.0 million for the same period in 2018.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

- FINANCIAL TABLES FOLLOW -

 

CHINA PHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)








September 30,


December 31,



2019


2018

ASSETS





Current Assets:





Cash and cash equivalents


$         761,606


$      1,186,587

Restricted cash


489,208


1,273,940

Banker's acceptances


-


20,579

Trade accounts receivable, less allowance for doubtful





accounts of $17,360,530 and $17,815,075, respectively


693,353


916,931

Other receivables, less allowance for doubtful





accounts of $46,644 and $34,884, respectively


189,524


170,098

Advances to suppliers


2,933


47

Inventory


3,973,373


5,054,975

Prepaid expenses


129,248


123,759

Total Current Assets


6,239,245


8,746,916






Advances for purchases of intangible assets


16,595,462


17,069,587

Property, plant and equipment, net


16,697,256


19,294,379

Operating lease right of use asset


157,177


-

Intangible assets, net


211,491


266,443

TOTAL ASSETS


$    39,900,631


$    45,377,325






LIABILITIES AND STOCKHOLDERS' EQUITY





Current Liabilities:





Trade accounts payable


$      1,158,067


$      1,060,934

Accrued expenses


140,753


310,804

Other payables


3,035,431


3,065,508

Advances from customers


498,768


525,647

Other payables - related parties


2,076,972


1,633,263

Operating lease liability, current portion


88,996


-

Current portion of construction loan facility


2,120,771


2,181,360

Bankers' acceptance notes payable


489,208


1,273,940

Total Current Liabilities


9,608,966


10,051,456

Non-current Liabilities:





Construction loan facility


2,120,771


4,362,720

Operating lease liability, net of current portion


70,952


-

Deferred tax liability


743,143


764,374

Total Liabilities


12,543,832


15,178,550

Commitments and Contingencies (Note 13)





Stockholders' Equity:





Preferred stock, $0.001 par value; 5,000,000 shares authorized;





no shares issued or outstanding


-


-

Common stock, $0.001 par value; 95,000,000 shares authorized;





43,579,557 shares and 43,579,557 shares outstanding, respectively


43,580


43,580

Additional paid-in capital


23,590,204


23,590,204

Accumulated deficit


(7,227,146)


(5,270,358)

Accumulated other comprehensive income


10,950,161


11,835,349

Total Stockholders' Equity


27,356,799


30,198,775

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY


$    39,900,631


$    45,377,325

 

 

CHINA PHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

(Unaudited)












For the Three Months


For the Nine Months



Ended September 30,


Ended September 30,



2019


2018


2019


2018

Revenue


$         2,376,844


$         2,298,472


$         7,875,525


$         9,087,867

Cost of revenue


2,004,085


1,785,927


6,682,688


6,942,141










Gross profit


372,759


512,545


1,192,837


2,145,726










Operating expenses:









Selling expenses


613,110


925,654


1,597,667


2,320,204

General and administrative expenses


333,833


327,161


1,097,200


1,172,314

Research and development expenses


39,716


62,059


175,642


107,946

Bad debt expense


31,304


1,129,105


54,708


1,481,786

Total operating expenses


1,017,963


2,443,979


2,925,217


5,082,250










Loss from operations


(645,204)


(1,931,434)


(1,732,380)


(2,936,524)










Other income (expense):









Interest income


11,840


16,113


27,216


27,931

Interest expense


(67,590)


(101,683)


(251,624)


(361,365)

Net other expense


(55,750)


(85,570)


(224,408)


(333,434)










Loss before income taxes


(700,954)


(2,017,004)


(1,956,788)


(3,269,958)

Income tax expense


-


160,485


-


111,910

Net loss


(700,954)


(1,856,519)


(1,956,788)


(3,158,048)

Other comprehensive income - foreign currency









translation adjustment


(909,889)


(1,535,424)


(885,188)


(2,280,131)

Comprehensive loss


$        (1,610,843)


$        (3,391,943)


$        (2,841,976)


$        (5,438,179)

Loss per share:









Basic and diluted


$                 (0.02)


$                 (0.04)


$                 (0.04)


$                 (0.07)

Weighted average shares outstanding


43,579,557


43,579,557


43,579,557


43,579,557

 

 

CHINA PHARMA HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)



For the Nine Months



Ended September 30,



2019


2018

Cash Flows from Operating Activities:





Net loss


$     (1,956,788)


$     (3,158,048)

Depreciation and amortization


2,261,800


2,499,114

Bad debt expense


54,708


1,481,786

Deferred income taxes


-


69,614

Inventory write off


87,542


-

Changes in assets and liabilities:





Trade accounts and other receivables


(407,733)


(514,428)

Advances to suppliers


(2,980)


106,981

Inventory


1,436,878


471,995

Trade accounts payable


130,642


(516,263)

Accrued taxes payable


23,321


(114,432)

Other payables and accrued expenses


(201,831)


580,689

Advances from customers


(12,670)


86,675

Prepaid expenses


(9,211)


14,005

Net Cash Provided by Operating Activities


1,403,678


1,007,688






Cash Flows from Investing Activities:





Purchases of property and equipment


(85,739)


(33,332)

Net Cash Used in Investing Activities


(85,739)


(33,332)






Cash Flows from Financing Activities:





Payments of construction term loan


(2,188,463)


(2,303,410)

Loan from related party


674,405


-

Repayments to related party


(209,726)


-

Net Cash Used in Financing Activities


(1,723,784)


(2,303,410)






Effect of Exchange Rate Changes on Cash


(19,136)


(33,531)

Net (Decrease) Increase in Cash and Cash Equivalents


(424,981)


(1,362,585)

Cash and Cash Equivalents at Beginning of Period


1,186,587


2,030,214

Cash and Cash Equivalents at End of Period


$          761,606


$          667,629






Supplemental Cash Flow Information:





Cash paid for income taxes


$                      -


$                      -

Cash paid for interest


$          241,465


$          351,206






Supplemental Noncash Investing and Financing Activities:





Issuance of banker's acceptances


$              2,641


$          847,527

Accounts receivable collected with banker's acceptances


532,537


462,642

Inventory purchased with banker's acceptances


553,183


502,473

Right-of-use assets obtained in exchange for operating lease obligations


231,130


-

 

Cision View original content:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-third-quarter-2019-financial-results-300958976.html

SOURCE China Pharma Holdings, Inc.

Copyright CNW Group 2019

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).